#USA #Fremont #Alzheimer's Disease #Alamar Biosciences #NULISAqpcr

Alamar Biosciences Unveils NULISAqpcr™ AD 5-Plex Assay

In an exciting development, Alamar Biosciences, Inc., a leader in precision proteomics, has announced the launch of its innovative NULISAqpcr™ AD 5-plex Assay aimed at bolstering Alzheimer's research. This assay represents a significant leap in the ability to detect crucial biomarkers in blood, which are pivotal to understanding Alzheimer's disease and other neurodegenerative conditions.

What is the NULISAqpcr™ AD 5-Plex Assay?

The NULISAqpcr AD 5-plex Assay is designed for research use only and allows simultaneous measurement of five essential biomarkers. These include brain-derived phosphorylated tau 217 (BD-pTau217), neurofilament light chain (NfL), amyloid-beta 42 (Aβ42), glial fibrillary acidic protein (GFAP), and the APOE4 carrier status. This unique capability enables researchers to gather comprehensive insights from a single blood or plasma sample, streamlining the process of studying Alzheimer's disease.

Key Features of the Assay

What sets the NULISAqpcr AD 5-plex Assay apart is its remarkable sensitivity and specificity. Due to the integration of multiple biomarkers within a single multiplex format, researchers benefit from an efficient and user-friendly experience. The assay offers reliable monitoring of amyloid and tau pathology, neurodegeneration, and inflammation while accurately determining the APOE4 carrier status, known as a significant genetic risk factor for Alzheimer’s disease.

Dr. Yuling Luo, the founder and CEO of Alamar, expressed pride in this cutting-edge development, stating, "The introduction of the NULISAqpcr AD 5-plex Assay marks a major milestone in our efforts to provide precise proteomic solutions for neurodegenerative diseases. By merging these critical protein targets into one assay with an optimized workflow, we aim to advance screening, early detection, and precision diagnostics for Alzheimer’s disease."

The Changing Landscape of Alzheimer's Research

Dr. Steven Williams, Alamar's Chief Scientific Officer, highlighted the transformative impact of blood-based biomarkers in Alzheimer’s research. He commented, "Blood-based biomarkers are revolutionizing Alzheimer’s research by offering an accurate, cost-effective, and accessible method for early detection and determination of therapy eligibility. Traditional single-plex assays could measure these biomarkers individually but required multiple tests to achieve a complete picture of the disease. NULISA™ changes that by enabling simultaneous measurement of multiple Alzheimer-related proteins in blood, each providing unique insights into the underlying pathophysiology."

Alamar is committed to collaboration with researchers, clinicians, and industry partners to advance precision proteomics and enhance treatment outcomes for patients with Alzheimer’s and other neurodegenerative diseases. The NULISAqpcr AD 5-plex Assay is now available as part of Alamar's Technology Access Program.

For further information about the NULISAqpcr AD 5-plex Assay and Alamar's complete portfolio of precision proteomics solutions, visit Alamar Biosciences.

About Alamar Biosciences, Inc.

Alamar Biosciences is a privately held life sciences company dedicated to advancing precision proteomics to enable the earliest possible disease detection. Its platform utilizes proprietary NULISA™ technology and the ARGO™ HT System designed for high sensitivity, addressing the key limitations of existing technologies to facilitate precise proteomics.

• ---